AVTR vs. NVS: Avantor vs. Novartis Stock Comparison
How do Avantor (AVTR) and Novartis (NVS) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Avantor (AVTR) and Novartis (NVS) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but AVTR is classified in Life Sciences Tools & Services while NVS is classified in Pharmaceuticals.
Avantor (AVTR) trades as ordinary local shares, while Novartis (NVS) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.
| Profile Item | AVTR | NVS |
|---|---|---|
| Name | Avantor, Inc. | Novartis AG Sponsored ADR |
| Country/Region | United States | Switzerland |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Life Sciences Tools & Services | Pharmaceuticals |
| GICS Sub-Industry | Life Sciences Tools & Services | Pharmaceuticals |
| Market Capitalization | 10.48 billion USD | 307.00 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | NYSE |
| Listing Date | May 17, 2019 | November 7, 1996 |
| Security Type | Common Stock | ADR |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | AVTR | NVS |
|---|---|---|
| Total Return (1Y) | 36.41% | 32.98% |
| Total Return (3Y, Annualized) | -5.02% | 24.72% |
| Total Return (5Y, Annualized) | -16.62% | 18.80% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | AVTR | NVS |
|---|---|---|
| Volatility (1Y, Annualized) | 43.39% | 27.12% |
| Beta (5Y) | 0.94 | 0.41 |
| Max Drawdown (5Y) | -82.42% | -20.42% |
| Avg. Volume (3M) | 8.56M | 2.07M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | AVTR | NVS |
|---|---|---|
| Sharpe Ratio (1Y) | 0.74 | 1.06 |
| Sortino Ratio (1Y) | 1.17 | 1.46 |
Profitability
ROE (TTM)
Novartis (NVS) at 24.33% sits in the top ROE quartile, while Avantor (AVTR) at 5.91% is closer to the peer norm — stronger capital efficiency for NVS.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.91%
- Max
- 109.18%
- Q3
- 6.23%
- AVTR
- 5.91%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
NVS
Pharmaceuticals, Biotechnology & Life Sciences industry group
24.33%
- Max
- 109.18%
- NVS
- 24.33%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
For every dollar of sales, both Avantor (AVTR) at 5.08% and Novartis (NVS) at 17.49% retain more as net profit than most peers, landing in the top net margin quartile of their industries.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.08%
- Max
- 18.05%
- AVTR
- 5.08%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
NVS
Pharmaceuticals, Biotechnology & Life Sciences industry group
17.49%
- Max
- 18.05%
- NVS
- 17.49%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Novartis (NVS) at 34.27% operates in the top operating margin quartile, ahead of Avantor (AVTR) at 8.19%, which runs around its industry’s norm.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.19%
- Max
- 83.12%
- Q3
- 14.77%
- AVTR
- 8.19%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
NVS
Pharmaceuticals, Biotechnology & Life Sciences industry group
34.27%
- Max
- 83.12%
- NVS
- 34.27%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | AVTR | NVS |
|---|---|---|
| ROE (TTM) | 5.91% | 24.33% |
| ROA (TTM) | 2.83% | 10.86% |
| Net Margin (TTM) | 5.08% | 17.49% |
| Operating Margin (TTM) | 8.19% | 34.27% |
| Gross Margin (TTM) | 31.59% | 75.21% |
Growth
Revenue Growth
Novartis (NVS) at 9.57% is around its peer norm for revenue growth, while Avantor (AVTR) at -3.41% drops into the bottom quartile, signaling weaker demand or pricing momentum.
EPS Growth
Novartis (NVS) at 21.81% is around its peer norm for EPS growth, while Avantor (AVTR) at -175.00% drops into the bottom quartile, signaling weaker earnings momentum.
Growth Metrics
| Metric | AVTR | NVS |
|---|---|---|
| Revenue Growth (YoY) | -3.41% | 9.57% |
| Revenue Growth (3Y CAGR) | -4.46% | 9.25% |
| EPS Growth (YoY) | -175.00% | 21.81% |
| EPS Growth (3Y CAGR) | -- | 31.14% |
Financial Strength
Current Ratio (MRQ)
Both Avantor (AVTR) at 1.89 and Novartis (NVS) at 0.88 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.89
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- AVTR
- 1.89
- Min
- 0.10
NVS
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.88
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- NVS
- 0.88
- Min
- 0.10
Debt / Equity (MRQ)
Avantor (AVTR) at 0.63 carries an industry-typical debt-to-equity mix, while Novartis (NVS) at 1.29 uses more debt funding than most peers.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.63
- Max
- 1.42
- Q3
- 0.65
- AVTR
- 0.63
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
NVS
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.29
- Max
- 1.42
- NVS
- 1.29
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | AVTR | NVS |
|---|---|---|
| Current Ratio (MRQ) | 1.89 | 0.88 |
| Debt / Equity (MRQ) | 0.63 | 1.29 |
| Net Debt / EBITDA | 3.40 | 1.64 |
Dividends
Dividend Yield (TTM)
Avantor (AVTR) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Novartis (NVS) reports a yield of 2.88%, ranking against industry peers normally.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- AVTR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
NVS
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.88%
- NVS
- 2.88%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Avantor (AVTR) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Novartis (NVS) reports a payout of 90.46%, ranking against industry peers normally.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- AVTR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
NVS
Pharmaceuticals, Biotechnology & Life Sciences industry group
90.46%
- NVS
- 90.46%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | AVTR | NVS |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 2.88% |
| Dividend Payout Ratio (TTM) | 0.00% | 90.46% |
Valuation
P/E Ratio (TTM)
Both Avantor (AVTR) at 30.94 and Novartis (NVS) at 31.02 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
30.94
- Max
- 85.34
- Q3
- 43.46
- AVTR
- 30.94
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
NVS
Pharmaceuticals, Biotechnology & Life Sciences industry group
31.02
- Max
- 85.34
- Q3
- 43.46
- NVS
- 31.02
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
Avantor (AVTR) at 1.58 sits in the cheaper P/S ratio quartile while Novartis (NVS) at 5.35 prices around its industry’s middle — AVTR costs less per dollar of sales, though read it alongside growth and margins.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.58
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- AVTR
- 1.58
- Min
- 0.01
NVS
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.35
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- NVS
- 5.35
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Avantor (AVTR) at 1.80 is valued about in line with its industry on P/B ratio, while Novartis (NVS) at 8.25 carries an above-peer premium to book — NVS is pricier on assets.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.80
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- AVTR
- 1.80
- Q1
- 1.69
- Min
- -5.59
NVS
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.25
- Max
- 13.53
- NVS
- 8.25
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | AVTR | NVS |
|---|---|---|
| P/E Ratio (TTM) | 30.94 | 31.02 |
| P/S Ratio (TTM) | 1.58 | 5.35 |
| P/B Ratio (MRQ) | 1.80 | 8.25 |
| Free Cash Flow Yield (TTM) | 4.21% | 3.67% |